Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients

Lasse H. Jakobsen*, Fredrik Ellin, Knut B. Smeland, Tove Wästerlid, Jacob H. Christensen, Judit M. Jørgensen, Pär L. Josefsson, Andreas K. Øvlisen, Harald Holte, Yngvild N. Blaker, Jacob H. Grauslund, Jon Bjørn, Daniel Molin, Ingemar Lagerlöf, Karin E. Smedby, Katherine Colvin, Gita Thanarajasingam, Matthew J. Maurer, Thomas M. Habermann, Kevin W. SongKatie Y. Zhu, Alina S. Gerrie, Chan Y. Cheah, Tarec C. El-Galaly

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

68 Downloads (Pure)

Fingeraftryk

Dyk ned i forskningsemnerne om 'Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients'. Sammen danner de et unikt fingeraftryk.

Medicin og biovidenskab